Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
48 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02584933 | Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study | active not recruiting | Phase 4 | 233 | Novartis PharmaceuticalsINDUSTRY | 21 | Sep 17, 2026 | clinicaltrials |
| NCT03975829 | Pediatric Long-Term Follow-up and Rollover Study | active not recruiting | Phase 4 | 163 | Novartis PharmaceuticalsINDUSTRY | 19 | Aug 27, 2026 | clinicaltrials |
| NCT02386800 | CINC424A2X01B Rollover Protocol | active not recruiting | Phase 4 | 279 | Novartis PharmaceuticalsINDUSTRY | 25 | Aug 20, 2026 | clinicaltrials |
| NCT04877522 | Asciminib Roll-over Study | recruiting | Phase 4 | 347 | Novartis PharmaceuticalsINDUSTRY | 29 | Jul 6, 2026 | clinicaltrials |
| NCT05203172 | The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials | recruiting | Phase 4 | 46 | PfizerINDUSTRY | 17 | Apr 7, 2026 | clinicaltrials |
| NCT05160922 | Crizotinib Continuation Clinical Study | active not recruiting | Phase 4 | 27 | PfizerINDUSTRY | 5 | Mar 30, 2026 | clinicaltrials |
| NCT04373564 | Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years(ODYSSEY) | recruiting | Phase 4 | 2,076 | GuerbetINDUSTRY | 8 | Jan 22, 2026 | clinicaltrials |
| NCT03229200 | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | active not recruiting | Phase 4 | 297 | Pharmacyclics Switzerland GmbHINDUSTRY | 17 | Oct 30, 2025 | clinicaltrials |
| NCT01496313 | To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer | completed | Phase 4 | 81 | SanofiINDUSTRY | 9 | Oct 3, 2025 | clinicaltrials |
| NCT01896479 | A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer(EXAMINER) | active not recruiting | Phase 4 | 247 | ExelixisINDUSTRY | 14 | Sep 2, 2025 | clinicaltrials |
| NCT02312960 | Radium-223 Dichloride Long-term Follow-up Program | completed | Phase 4 | 255 | BayerINDUSTRY | 22 | Mar 25, 2025 | clinicaltrials |
| NCT04078152 | Durvalumab Long-Term Safety and Efficacy Study(WAVE) | completed | Phase 4 | 163 | AstraZenecaINDUSTRY | 31 | Dec 20, 2024 | clinicaltrials |
| NCT01794793 | Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies | completed | Phase 4 | 337 | RECORDATI GROUPINDUSTRY | 28 | Oct 1, 2024 | clinicaltrials |
| NCT04574947 | Lidocaine And Neuromonitoring in Thyroid Surgery | completed | Phase 4 | 110 | Saint Petersburg State University, RussiaOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT01735955 | Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study | completed | Phase 4 | 57 | Novartis PharmaceuticalsINDUSTRY | 16 | Feb 8, 2024 | clinicaltrials |
| NCT02869789 | An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers | completed | Phase 4 | 1,041 | Bristol-Myers SquibbINDUSTRY | 21 | Jun 15, 2023 | clinicaltrials |
| NCT05046028 | Individualization of Nutritive Sensory Support Of Radiation Therapy | completed | Phase 4 | 100 | National Medical Research Radiological Centre of the Ministry of Health of RussiaOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05518383 | B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 | recruiting | Phase 4 | 300 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT04999618 | A New Approach in Laser Surgery Using the Regenerative Solution in Children Diagnosed With Vascular Pathology(DOUBLE-SKIN) | completed | Phase 4 | 200 | Center for Vascular Pathology, MoscowOTHER | 1 | Nov 4, 2021 | clinicaltrials |
| NCT05106179 | The Efficacy and Safety of Beta-blockers Drugs in Adults With Spinal Hemangioma | unknown | Phase 4 | 1,000 | Center for Vascular Pathology, MoscowOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT02092467 | Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis | completed | Phase 4 | 4,372 | PfizerINDUSTRY | 30 | Aug 17, 2021 | clinicaltrials |
| NCT01789281 | Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study. | completed | Phase 4 | 34 | Novartis PharmaceuticalsINDUSTRY | 9 | Jun 11, 2021 | clinicaltrials |
| NCT04747951 | Total Neoadjuvant Therapy in Rectal Cancer Treatment | unknown | Phase 4 | 280 | State Scientific Centre of Coloproctology, Russian FederationOTHER_GOV | 1 | Feb 15, 2021 | clinicaltrials |
| NCT00381095 | A Study To Evaluate Pregabalin In The Treatment Of Moderate To Severe Chronic Bone Pain Related To Metastatic Cancer(COPE) | terminated | Phase 4 | 152 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc.INDUSTRY | 19 | Jan 20, 2021 | clinicaltrials |
| NCT01739764 | An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol | completed | Phase 4 | 215 | Hoffmann-La RocheINDUSTRY | 25 | Jan 7, 2021 | clinicaltrials |
| NCT01753297 | A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.(PRIORITI) | completed | Phase 4 | 226 | IpsenINDUSTRY | 2 | Dec 9, 2020 | clinicaltrials |
| NCT01588184 | An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study | completed | Phase 4 | 95 | Hoffmann-La RocheINDUSTRY | 21 | Nov 5, 2020 | clinicaltrials |
| NCT01206764 | A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma. | completed | Phase 4 | 143 | Novartis PharmaceuticalsINDUSTRY | 10 | Jun 24, 2019 | clinicaltrials |
| NCT03550482 | Oncoxin® and Quality of Life in Cancer Patients | completed | Phase 4 | 133 | Catalysis SLINDUSTRY | 2 | Jun 5, 2019 | clinicaltrials |
| NCT03514550 | Effects of Anesthesia on Immunity in Cancer | completed | Phase 4 | 20 | Meshalkin Research Institute of Pathology of CirculationNETWORK | 1 | Jun 3, 2019 | clinicaltrials |
| NCT01180049 | Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma | completed | Phase 4 | 101 | PfizerINDUSTRY | 11 | May 20, 2019 | clinicaltrials |
| NCT01283386 | A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status | terminated | Phase 4 | 26 | Hoffmann-La RocheINDUSTRY | 1 | Mar 14, 2019 | clinicaltrials |
| NCT01271010 | A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status | terminated | Phase 4 | 89 | Hoffmann-La RocheINDUSTRY | 1 | Mar 20, 2018 | clinicaltrials |
| NCT00430352 | MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. | completed | Phase 4 | 545 | Hoffmann-La RocheINDUSTRY | 24 | Aug 14, 2017 | clinicaltrials |
| NCT00776425 | A Study of the Quality of Life and Treatment Response to Once Weekly Epoetin Beta (Recormon) Treatment in Anemic Participants With Solid and Lymphoid Malignancies | completed | Phase 4 | 117 | Hoffmann-La RocheINDUSTRY | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00949910 | An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 4 | 6,586 | Hoffmann-La RocheINDUSTRY | 51 | Oct 5, 2016 | clinicaltrials |
| NCT01066884 | A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 4 | 5 | Hoffmann-La RocheINDUSTRY | 1 | Aug 24, 2016 | clinicaltrials |
| NCT00451906 | A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer. | completed | Phase 4 | 2,252 | Hoffmann-La RocheINDUSTRY | 40 | May 24, 2016 | clinicaltrials |
| NCT00502671 | A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer. | completed | Phase 4 | 228 | Hoffmann-La RocheINDUSTRY | 1 | Sep 3, 2015 | clinicaltrials |
| NCT01950871 | Prostate Guided Biopsy Study Evaluating the Diagnostic Performance of Prostate HistoScanning(PHSTT-01) | terminated | Phase 4 | 80 | Advanced Medical Diagnostics s.a.INDUSTRY | 18 | Jan 5, 2015 | clinicaltrials |
| NCT02027337 | Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants | unknown | Phase 4 | 200 | Tyumen State Medical AcademyOTHER | 1 | Nov 21, 2014 | clinicaltrials |
| NCT01587430 | 3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia | unknown | Phase 4 | 245 | National Research Center for Hematology, RussiaNETWORK | 1 | Apr 7, 2014 | clinicaltrials |
| NCT02056587 | Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment | completed | Phase 4 | 37 | Kidney Cancer Research BureauOTHER | 1 | Feb 6, 2014 | clinicaltrials |
| NCT00090038 | Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma | completed | Phase 4 | 168 | BiogenINDUSTRY | 11 | Oct 20, 2009 | clinicaltrials |
| NCT00050999 | Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients | completed | Phase 4 | 195 | Eisai Inc.INDUSTRY | 10 | Mar 5, 2008 | clinicaltrials |
| NCT00051012 | Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients | completed | Phase 4 | 86 | Eisai Inc.INDUSTRY | 9 | Mar 5, 2008 | clinicaltrials |
Data updated 12 days agoSource updated unknownsource: clinicaltrials